<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Complete loss or deletion of the long arm of chromosome 5 is frequent in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The putative gene(s) deleted and responsible for the pathogenesis of these poor prognosis <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> remain controversial </plain></SENT>
<SENT sid="2" pm="."><plain>This study is a comprehensive analysis of previously implicated and novel genes for epigenetic inactivation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In 146 AML cases, methylation of CTNNA1 was frequent, and more common in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients with 5q deletion (31%) than those without 5q deletion (14%), whereas no methylation of other 5q genes was observed </plain></SENT>
<SENT sid="4" pm="."><plain>In 31 MDS cases, CTNNA1 methylation was only found in high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (&gt;or=<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e>), but not in low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (&lt;<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e>), indicating that CTNNA1 methylation might be important in the transformation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>CTNNA1 expression was lowest in <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> patients with CTNNA1 methylation, although reduced expression was found in some patients without promoter methylation </plain></SENT>
<SENT sid="6" pm="."><plain>Repressive chromatin marks (H3K27me3) at the promoter were identified in CTNNA1-repressed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell lines and primary <z:hpo ids='HP_0001909'>leukemias</z:hpo>, with the most repressive state correlating with DNA methylation </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest progressive, acquired epigenetic inactivation at CTNNA1, including <z:chebi fb="0" ids="15358">histone</z:chebi> modifications and promoter CpG methylation, as a component of <z:hpo ids='HP_0001909'>leukemia</z:hpo> progression in patients with both 5q- and non-5q- <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
</text></document>